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Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD95 ligand (CD95L) are potent inducers of apoptosis in
various tumour cell types. Death receptors DR4 and DR5 can induce and decoy receptors DcR1 and DcR2 can inhibit TRAIL-
mediated apoptosis. The study aim was to investigate whether anticancer agents can modulate similarly TRAIL-receptor and CD95
membrane expression and TRAIL and CD95L sensitivity.Three colon carcinoma cell lines (Caco-2, Colo320 and SW948) were
treated with 5-fluorouracil (5-FU), cisplatin or interferon-g. TRAIL-receptor and CD95 membrane expression was determined flow
cytometrically. Sensitivity to TRAIL or CD95L agonistic anti-CD95 antibody was determined with cytotoxicity and apoptosis assays.
SW948 showed highest TRAIL sensitivity. The protein synthesis inhibitor cycloheximide decreased FLICE-like inhibitory protein levels
in all cell lines, and the TRAIL-resistant cell lines Caco-2 and Colo320 became sensitive for TRAIL. Exposure of the cell lines to 5-FU,
cisplatin and interferon-g left TRAIL-receptor membrane expression and TRAIL sensitivity unaffected. CD95 membrane expression
and anti-CD95 sensitivity was, however, modulated by the same drugs in all lines. Cisplatin and interferon-g raised CD95 membrane
levels 6–8-fold, interferon-g also increased anti-CD95 sensitivity. These results indicate that the CD95 and TRAIL pathways use
different mechanisms to respond to various anticancer agents. Induced CD95 membrane upregulation was associated with increased
anti-CD95 sensitivity, whereas no upregulation of TRAIL-receptor membrane expression or TRAIL sensitisation could be established.
For optimal use of TRAIL-mediated apoptosis for cancer therapy in certain tumours, downregulation of intracellular inhibiting factors
may be required.
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Colorectal cancer is the third most frequent cause of cancer-related
death (Ilyas et al, 1999). Since resistance to chemotherapeutic
drugs remains a major problem in the treatment of this disease, the
use of death receptor ligands as potential therapeutic agents is of
great interest. The death receptor ligands tumour necrosis factor-a
(TNF-a), CD95 ligand (CD95L) and TNF-related apoptosis-
inducing ligand (TRAIL) induce apoptosis in a variety of cells
after ligation with their receptors. TRAIL shows great homology
with CD95L. Certain cellular apoptotic proteins are involved in the
cellular pathways of both ligands, suggesting that these pathways
converge to some extent. Systemic use of CD95 is impossible due
to severe toxic side effects. TRAIL on the other hand is a potent
inducer of apoptosis in cancer cells in vitro (Wiley et al, 1995; Pitti
et al, 1996) and in its native biological form, it exhibits antitumour
activity in several xenograft studies in vivo without serious toxicity
(Ashkenazi et al, 1999; Gliniak and Le, 1999; Walczak et al, 1999).
TRAIL can bind to four membrane receptors. Two of these
receptors, DR4 (Pan et al, 1997b) and DR5 (Chaudhary et al, 1997;
MacFarlane et al, 1997; Pan et al, 1997a; Schneider et al, 1997;
Sheridan et al, 1997), are receptors that contain a cytoplasmic
death domain through which TRAIL can mediate an apoptotic
signal to the cell. Two other receptors, DcR1 and DcR2 can also
bind TRAIL, but lack an intact death domain (Degli-Eposti et al,
1997; MacFarlane et al, 1997; Marsters et al, 1997; Pan et al, 1997a,
1998; Sheridan et al, 1997). Consequently, DcR1 and DcR2 are
thought to act as decoy receptors, protecting the cell from
apoptosis (Pan et al, 1997a; Sheridan et al, 1997).
TRAIL binds as a homotrimer to DR4 and DR5, which upon
binding will trimerise and form a death-inducing signalling
complex. Initiator caspases, such as caspase 8, will be activated
by autocleavage and activate downstream effector caspases such as
caspase 3, and finally the cell will go into apoptosis (Ashkenazi and
Dixit, 1998).
Treatment with cytokines and chemotherapeutic drugs can
upregulate protein levels (Nimmanapalli et al, 2001) and mRNA of
DR4 and DR5 in p53-dependent or independent ways (Sheikh et al,
1998; Wu et al, 2000) and augment TRAIL sensitivity (Keane et al,
1999; Nimmanapalli et al, 2001). However, almost no studies have
looked into whether anticancer drugs can change TRAIL-receptor
membrane expression, while this effect has been described for
CD95 (Timmer et al, 2002). Furthermore, it is not known whether
this change in receptor expression levels at the cell surface or
expression levels of pro- and antiapoptotic proteins are the key
determinants for sensitivity to TRAIL or CD95L. To address these
questions, we studied membrane expression levels of TRAIL
receptors in relation to TRAIL sensitivity in a panel of three colon
carcinoma cell lines. Furthermore, we analysed modulation of
TRAIL-receptor membrane expression and TRAIL sensitivity by
anticancer drugs. We compared this outcome with the effect these
drugs exhibit on the CD95-receptor and sensitivity to agonistic
anti-CD95 in the three colon carcinoma cell lines. In addition, we
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sanalysed how downregulation of intracellular components of the
apoptotic pathways was related to TRAIL sensitivity and sensitivity
to anti-CD95. From the results we can conclude that the CD95
pathway and the TRAIL pathway respond differently to various
anticancer agents.
MATERIALS AND METHODS
Reagents
RPMI 1640 medium was obtained from Life Technologies (Breda,
The Netherlands) and foetal calf serum (FCS) from Bodinco BV
(Alkmaar, The Netherlands). Cisplatin and 5-fluorouracil (5-FU)
were purchased from Pharmachemie BV (Haarlem, The Nether-
lands), interferon-g was obtained from Roche Diagnostics
(Mannheim, Germany) and TNF-a was kindly provided by
Boehringer Ingelheim (Ingelheim am Rhein, Germany). 3-(4,5-
Dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT)
and cycloheximide were purchased from Sigma-Aldrich (Zwijn-
drecht, The Netherlands). Anti-CD95 7C11 was obtained from
Immunotech (Marseille, France). Recombinant human TRAIL
(rhTRAIL) was produced noncommercially in cooperation with
IQ-Corporation (Groningen, The Netherlands) following a proto-
col described elsewhere (Ashkenazi et al, 1999). The TRAIL-
receptor antibodies used for flow cytometry were obtained from
Immunex Corporation (Seattle, WA, USA).
Cell lines
For this study, the colon carcinoma cell lines Caco-2 (Fogh et al,
1977), Colo320 (Quinn et al, 1979) and SW948 (Leibovitz et al,
1976) were used. Caco-2 and Colo320 were cultured in RPMI 1640
medium supplemented with, respectively, 13 and 10% foetal calf
serum at 371C in a humidified atmosphere with 5% CO2. SW948
was cultured in Leibovitz L15-RPMI 1640 (1:1) enriched with 10%
FCS, 0.05 M pyruvate, 0.1 M glutamine and 0.025% b-mercaptoetha-
nol at 371C in a humidified atmosphere with 5% CO2. Caco-2 and
SW948 were harvested by treatment with protease XXIV for
5–10min at 371C.
Cytotoxicity assay
The microculture tetrazolium assay was used to determine
cytotoxicity. In a total volume of 200ml, 3750 cells for Caco-2,
1000 cells for Colo320 and 3750 cells for SW948 were incubated.
Treatment consisted of continuous incubation with various
concentrations of 5-FU or interferon-g with or without anti-
CD95 or rhTRAIL. Treatment with cisplatin consisted of 24h
preincubation with cisplatin alone before adding anti-CD95 or
rhTRAIL. After an incubation period of 96h, 20ml of MTT-solution
(5mgml
 1 phosphate-buffered saline (PBS: 6.4mM Na2HPO4;
1.5mM KH2PO4; 0.14mM NaCl; 2.7mM KCl; pH¼7.2)) was added
for 3.75h. Subsequently, plates were centrifuged and the super-
natant aspirated. After dissolving the formazan crystals by adding
dimethyl sulphoxide (Merck, Amsterdam, The Netherlands), plates
were read immediately at 520nm using a microtitre well spectro-
meter (Bio-Rad microplate reader, Bio-Rad laboratories B.V.,
Veenendaal, The Netherlands). Controls consisted of media
without cells. Cell survival was defined as the growth of treated
cells compared to untreated cells. IC50 is the concentration of drug
inhibiting survival by 50%. Mean cytotoxicity was determined in
three independent experiments, each performed in quadruplicate.
Sodium dodecyl sulphate (SDS)–polyacrylamide gel
electrophoresis (PAGE) and Western blotting
Cells were washed twice in cold PBS. Then they were lysed in SDS
sample buffer (10% 2-b-mercaptoethanol, 4% SDS, 0.5 M Tris-HCl,
pH 6.8 and 20% glycerol, 0.002% bromophenol blue) and boiled in
a waterbath for 5min. Proteins were separated on a polyacryla-
mide SDS containing gel and transferred to a polyvinylidene
difluoride membrane (PVDF membrane) (Millipore BV, Etten-
Leur, The Netherlands). Nonspecific binding sites were blocked
with 5% skimmed milk (Fluka) in TBS-Tween (TBS with 0.05%
TWEEN (Sigma, Aldrich (Zwyndrecht, The Netherlands))) for at
least 1h at room temperature. After blocking, the membranes were
incubated with specific antibodies for 1h at room temperature. To
detect CD95-associated death domain (FADD), X-linked inhibitor
of apoptosis protein (XIAP), FLICE-like inhibitory protein (FLIP),
caspase 3, caspase 9, caspase 8, poly (ADP-ribose)-polymerase
(PARP), DR4, DR5, DcR2, CD95, p53 and Fas-associated phos-
phatase-1 (FAP-1), CD95L and TRAIL, the following antibodies
were used: mouse-anti-FADD, mouse-anti-XIAP and mouse-anti-
CD95L from Transduction Laboratories (Lexington, KY, USA),
rabbit-anti-caspase 3 and rabbit-anti-caspase 9 from Pharmingen
(Becton Dickinson, Erebodegem-Aalst, Belgium), rabbit-anti-
PARP from Roche Diagnostics (Mannheim, Germany), goat-anti-
DR4, goat-anti-CD95, mouse-anti-p53, goat-anti-TRAIL(K18) and
goat-anti-FAP-1 from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) rabbit-anti-DR5 and rabbit-anti-DcR2 from Oncogene
Research Products (Calbiochem-Novabiochem, Germany). Mouse
anti-caspase 8 was purchased from Cell Signaling Technology
(Leusden, The Netherlands). Mouse-anti-FLIP NF6 was kindly
provided by M Peter (Chicago, IL, USA). Mouse-antiactin was
obtained from ICN Biomedicals (Zoetermeer, The Netherlands).
The secondary antibodies were labelled with horseradish
peroxidase (all from DAKO, Glostrup, Denmark), and chemilumi-
nesence was detected using the ECL-chemiluminescence kit or
with the Lumi-Light Plus Western blotting kit (Roche Diagnostics,
Mannheim, Germany). Western blot analyses have been performed
at least three times. To study caspase 3 activation and PARP
cleavage, cells were treated with rhTRAIL, anti-CD95, cyclohex-
imide, or combinations of cycloheximide with rhTRAIL or anti-
CD95 for 24h. Concentrations of 5mgml
 1 cycloheximide,
0.1mgml
 1 rhTRAIL and 0.05mgml
 1 anti-CD95 were used, unless
indicated otherwise. Cells were pretreated with cycloheximide for
1h before adding rhTRAIL and anti-CD95. To analyse the effect of
cycloheximide on the protein level of FLIP-L, the cells were
pretreated 1h with cycloheximide before TRAIL or anti-CD95 was
added. For Caco-2 and Colo320 cell lines, the incubation was 24h, for
the TRAIL-sensitive cell line SW948 the incubation time was 5h for
TRAIL and 24h for anti-CD95. The Bradford (1976) assay was used to
determine protein concentrations in all samples. In all experiments,
samples containing 20mg lysate were used, and all membranes
were stained with Ponceau S to check for equal protein loading.
Protein expression levels were standardised to actin expression
and densitometrically analysed with Diversity One (Amersham
Biosciences Europe (Roosendaal, The Netherlands) software.
Flow cytometry
Analysis of CD95 and TRAIL-receptor membrane expression was
performed using a flow cytometer (Epics Elite, Coulter-Electronics,
Hialeah, FL, USA). Adherent cells were harvested by treatment
with protease (0.01 or 0.005%) for 5min at 371C and washed twice
in PBS at 41C. Appropriate concentrations of antibodies were
added to the cells in 50ml PBS containing 2% FCS and 0.1%
sodium azide. Cells were incubated for 30min on ice. Cells were
washed twice with cold PBS containing 2% FCS and 0.1% sodium
azide at 41C and incubated with FITC-conjugated rabbit-anti-
mouse (DAKO, Glostrup, Denmark) for 30min on ice. After
washing, a minimum of 5000 cells were analysed by flow
cytometry. For the TRAIL receptors, the mouse IgG1 and mouse
IgG2a antibodies (DAKO) were used as isotype controls.
PE-conjugated anti-CD95 antibody and a PE-conjugated mouse
IgG1k control were obtained from Pharmingen. Antibodies against
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sthe different TRAIL receptors were a gift of Immunex (Seattle, WA,
USA). For TRAIL-receptor 1, huTRAILR1-M271, for TRAIL-
receptor 2, huTRAILR2-M413, for TRAIL-receptor 3, huTRAILR3-
M430, and for TRAIL-receptor 4, huTRAILR4-M444 has been used.
Membrane receptor expression is shown as mean fluorescent inten-
sity (MFI) of all analysed cells. Membrane expression was observed
as an increase in fluorescence intensitiy for the whole analysed cell
population. All experiments are performed at least three times.
Reverse transcription–polymerase chain reaction
(RT–PCR)
Total RNA was isolated by guanine thiocyanate–phenol–chloro-
form extraction and treated with DNAse for 30min at 371Ct o
remove genomic DNA contamination. cDNA was synthesised from
5mg RNA as described by the manufacturer’s protocol (Life
Technologies, Breda, The Netherlands) using oligo (dT) primers
and MMLV transcriptase (Life Technologies, Breda, The Nether-
lands). The sequences for the relevant primers were as described
elsewhere (Griffith et al, 1998; Rieger et al, 1999). Annealing
temperatures for DR4, DR5, DcR1, DcR2 and TRAIL were 61, 61,
61, 60 and 621C, respectively. The DNA fragments were amplified
for 30 cycles using a thermal sequencer (Perkin Elmer Benelux
(Groningen, The Netherlands)). The program consisted of one
cycle of 961C for 1min, 30 cycles of 961C for 45s, the specific
annealing temperature for 45s, 721C for 45s and one cycle of 721C
for 10min. The PCR-amplified products of DR4, DR5, DcR1, DcR2
and TRAIL were, respectively, 506, 502, 612, 464, and 413bp in
size. PCR products were run on a 2% agarose gel in 1  Tris-
borate EDTA (TBE) buffer and were visualised under UV light.
PCR products were checked for the right size with restriction
enzymes. The housekeeping gene GAPDH was used as a control.
Apoptosis assay
From each cell line, 1.0 10
4 cells were seeded in 96-well plates
with or without interferon-g (10 or 100Uml
 1). After 24–30h
incubation at 371C, cycloheximide (5mgml
 1) was added. After 1h
incubation with cycloheximide, rhTRAIL (0.1 or 1.0mgml
 1), anti-
CD95 (0.05mgml
 1) or TNF-a (0.1 or 1.0mgml
 1) was added and
the cells were incubated for 24h at 371C. Apoptosis was identified
by staining nuclear chromatin with acridine orange, identifying
morphological changes by fluorescence microscopy. Control cells
were seeded with medium, cycloheximide or interferon-g alone.
Apoptosis experiments were performed at least three times.
Caspase 3 activation assay
Activity of caspase 3 in Caco-2, Colo320 and SW948 cells treated
with 5mgml
 1 cycloheximide, 0.05mgml
 1 anti-CD95, 0.1mgml
 1
rhTRAIL or combinations of cycloheximide with anti-CD95 or
rhTRAIL was determined. Cells were exposed to these compounds
for 24h, except for SW948. For this cell line anti-CD95 incubations
were 24h, whereas rhTRAIL incubations were 3h. Activity of
caspase 3 was assayed according to the manufacturer’s instructions
using the fluorescence peptide substrate Ac-DEVD-AFC (Biomol
tebu-bio, Heerhugowaard, The Netherlands). Fluorescence from
free 7-amino-4-trifluoromethyl coumarin (AFC) was monitored in
a FL600 Fluorimeter Bio-tek plate reader (Beun de Ronde,
Abcoude, The Netherlands) using 380nm excitation and 508nm
emission wavelengths. Relative caspase 3 activity was expressed as
the ratio of treated to untreated cells. Experiments are performed
for at least three times. Values are mean7s.d.’s.
Statistics
Statistical an analysis was performed using the Student’s t-test.
P-values p0.05 were considered to be significant.
RESULTS
The three colon carcinoma cell lines differ in TRAIL
sensitivity
Sensitivity of the three colon carcinoma cell lines to the cytotoxic
activity of 0.001–1.0mgml
 1 rhTRAIL for 96h was determined
using the cytotoxicity assay (Figure 1A).
SW948 is very sensitive to rhTRAIL with an IC50 of
0.007mgml
 1. Caco-2 and Colo320 are resistant to rhTRAIL even
at the highest concentration of 1mgml
 1 (Figure 1A). The
cytotoxic effect of rhTRAIL is related to its ability to trigger
apoptotic cell death. As demonstrated in Figure 2, an increasing
concentration of rhTRAIL resulted in increasing percentage of
apoptotic cells in SW948. Apoptosis was also confirmed with
cleavage of caspase 3 and cleavage of the early apoptosis marker
PARP (Figure 3).
Determining the functionality of the TRAIL-mediated
apoptosis pathway
To further analyse the functionality of the TRAIL-mediated
apoptosis pathway in these three cell lines, TRAIL-receptor
expression on the mRNA, protein and membrane level was
determined. Since mRNAs of all TRAIL receptors and TRAIL
could be detected in the three cell lines using RT–PCR (Figure 4),
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Figure 1 Survival (%) of Caco-2 (closed square), Colo320 (closed
triangle) and SW948 (closed diamond), after continuous incubation with
(A) rhTRAIL and (B) anti-CD95 as measured by cytotoxicity assays. Values
are mean7s.d. of at least three independent experiments. *: SW948 differs
from Caco-2 and Colo320 at 0.01–1.0mgml
 1 rhTRAIL (Po0.05).
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sexpression of the receptors on the cell surface was studied by flow
cytometry. As demonstrated in Figure 5, SW948 expressed more
DR4 than DR5 on the membrane, whereas Caco-2 and Colo320
expressed similar levels of the death receptors on the surface.
Caco-2 and SW948 had very low or no expression of DcR1 or DcR2
on their surface, while Colo320 showed a low DcR2 expression.
Total protein expression of the TRAIL receptors in these cell
lines was studied by Western blot analysis (Figure 6). No difference
in protein expression was found for DR4. SW948 expressed less
DR5 than Caco-2 and Colo320. Colo320, the cell line with the
highest DcR2 expression on the surface, showed a higher DcR2
total protein expression. Although TRAIL mRNA expression was
found (Figure 4), no protein expression of TRAIL could be
detected in any of the cell lines (Figure 6B). To further characterise
these cell lines, expression levels of several important proteins
involved in CD95 and TRAIL-receptor-dependent apoptosis were
measured by Western blotting. A few important differences
between the cell lines were found and are shown in Figure 6.
Colo320 had a lower expression of caspase 8 and CD95L, but a
higher expression of XIAP. SW948 had a lower PARP expression,
but a higher expression of the inhibitor FAP-1. Caco-2 and SW948
did not express p53. No clear differences in protein expression
levels were found for FLIP, FADD, DR5, caspase 3, caspase 9 and
CD95.
In the presence of the protein synthesis inhibitor cycloheximide,
the TRAIL-resistant cell lines Caco-2 and Colo320 became sensitive
to rhTRAIL. Even at the lower concentration of 0.1mgml
 1
rhTRAIL, about 90% of the Caco-2 and Colo320 cells went into
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Figure 2 (A) Apoptosis assay for Caco-2, Colo320 and SW948. Cells
were incubated for 24h in medium; with 5mgml
 1 cycloheximide (CHX);
with 0.1 or 1.0mgml
 1 rhTRAIL; with the combination cycloheximide and
0.1 or 1.0mgml
 1 rhTRAIL. Values are mean7s.d. of at least three
independent experiments. *: the percentage apoptotic Caco-2 or Colo320
cells in the presence of cycloheximide plus rhTRAIL differs from the
percentage apoptotic cells in the presence of rhTRAIL alone (Po0.05). The
percentage of apoptotic SW948 cells in the presence of rhTRAIL differs
from the percentage of apoptotic cells in the control cells (Po0.05). (B)
Apoptosis assay for SW948. Cells were incubated for 3h in medium; with
5mgml
 1 cycloheximide; with 0.1, 0.01 or 0.001mgml
 1 rhTRAIL; with the
combination cycloheximide and 0.1, 0.01 or 0.001mgml
 1 rhTRAIL. Values
are mean7s.d. for at least three independent experiments. *: the
percentage of apoptotic SW948 cells in the presence of cycloheximide
plus rhTRAIL differs from the percentage of apoptotic cells in the presence
of rhTRAIL alone, (Po0.05).
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Figure 3 (A) Caspase 3 activity assay for Caco-2, Colo320 and SW948.
Cells were incubated as control in medium (black bars), cycloheximide
(light grey bars), anti-CD95 (dark grey bars), rhTRAIL (white bars) or
combinations of cycloheximide with anti-CD95 (striped bars) or
cycloheximide with rhTRAIL (spotted bars) as described in Materials and
Methods. Caspase 3 activity is expressed as the ratio of treated to
untreated cells. Experiments are performed for at least three times, values
are mean7s.d.’s. (B) Western blot analysis of PARP cleavage in Caco-2,
Colo320 and SW948 after treatment with cycloheximide, rhTRAIL, anti-
CD95, rhTRAIL and cycloheximide or anti-CD95 and cycloheximide. If cells
are apoptotic, full-length PARP (112kDa) is cleaved into an 85kDa
fragment. One representative of at least three different experiments is
shown. Actin (40kDa) is shown as a loading control.
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sapoptosis, and these levels are comparable with the level of
apoptosis seen in SW948 without cycloheximide. The fact that
Caco-2 and Colo320 become sensitive to rhTRAIL in the presence
of cycloheximide indicates that the TRAIL-mediated apoptotic
pathway is functional in these cell lines (Figures 2, 3). If lower
rhTRAIL concentrations and shorter incubation time were used,
cycloheximide also sensitised SW948 to rhTRAIL (Figure 2B). This
indicates that cycloheximide sensitises all three cell lines and that
it rendered the already sensitive cell line SW948 even more
sensitive. Cycloheximide also sensitised these cell lines for anti-
Caco-2 Colo320 SW948
DR4
DR5
DcR1
DcR2
TRAIL
Figure 4 Reverse transcription–PCR of TRAIL and TRAIL receptors in
Caco-2, Colo320 and SW948, as described in the Materials and Methods.
One representative of at least three different experiments is shown.
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Figure 5 Basic membrane expression of the TRAIL receptors DR4,
DR5, DcR1 and DcR2 and the CD95 receptor in Caco-2, Colo320 and
SW948 as determined by flow cytometry. (A) A representative example of
TRAIL-receptor membrane expression in SW948. Receptor expression
was detected as an increased fluorescence intensity of the whole cell
population and resulted in a peak shift to the right (1¼control; 2¼DcR1;
3¼DcR2; 4¼DR5; 5¼DR4). (B) TRAIL and CD95 receptor membrane
expression of Caco-2, Colo320 and SW948 expressed as MFI. Values are
mean7s.d. of at least three independent experiments. (C) The
percentages CD95 and TRAIL-receptor positive cells analysed with flow
cytometry. Values are mean7s.d.’s of three different experiments.
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Figure 6 (A) Western blot analysis of basic expression levels of several
proteins involved in TRAIL- and CD95-mediated apoptosis in Caco-2,
Colo320 and SW948 cells. One representative of at least three different
experiments is shown. Bands of interest are indicated with arrows. (B)
Western blot analysis of TRAIL protein expression in Caco-2, Colo320 and
SW948. Recombinant human TRAIL (50ng) was loaded as a positive
control. (C) Relative optical density of Caco-2 (black bars), Colo320
(striped bars) and SW948 (grey bars) protein expression of CD95L, DR5,
DcR2, caspase 8 (casp-8), FAP-1, PARP and XIAP. Protein expression was
corrected to actin expression and is expressed in relation to Caco-2
expression.
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CD95 with or without cycloheximide, but in the presence of
cycloheximide this cell line could be sensitised to TNF-a. Colo320
can only be sensitised by cycloheximide to anti-CD95 in
combination with interferon-g. The presence of cycloheximide
only slightly increases the percentage of TNF-a-mediated apopto-
sis. SW948 in contrast, can be sensitised to TNF-a as well as to
anti-CD95 by cycloheximide. Western blot showed that cyclohex-
imide treatment resulted in a decrease in FLIP-L protein level in all
cell lines with only an almost undetectable level in Colo320
(Figure 9). Treatment with rhTRAIL alone resulted in FLIP-L
cleavage into an intermediate product of 43kDa in all cell lines. In
the rhTRAIL-sensitive SW948 cell line, most FLIP-L was present as
the cleaved intermediate product, which is in agreement with the
observed caspase 3 activation and PARP cleavage (see Figure 3).
Cycloheximide in combination with rhTRAIL resulted in a
complete loss of the full-length FLIP-L and low levels of the
intermediate product. Incubation with cycloheximide had no effect
on Bax, Bcl2 and Bcl-XL protein levels in these cell lines (data not
shown).
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Figure 7 Anti-CD95-mediated apoptosis in Caco-2, Colo320 and
SW948 with or without 24h incubation with interferon-g (IFN). Values
are mean þs.d. of at least three independent experiments. 1: The
percentages of apoptotic cells treated with 10 or 1000Uml
 1 interferon-g
in the presence of cycloheximide plus anti-CD95 differ from the
percentage of apoptotic cells in the presence of cycloheximide plus anti-
CD95 in the untreated cells (Po0.05). 2: At the same concentration of
interferon-g, the percentage of apoptosis in cells treated with anti-CD95
differs from the percentage of apoptosis in cells treated with anti-CD95
and cycloheximide (Po0.05).
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 1 TNF-
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apoptotic cells treated with TNF-a and cycloheximide differ from the
percentages of apoptotic cells with TNF-a alone (Po0.05).
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Figure 9 (A) Western blot analysis determined that cycloheximide
(CHX) decreased FLIP protein levels in Caco-2, Colo320 and SW948.
After exposure to rhTRAIL or anti-CD95, full-length FLIP-L (55kDa) is
cleaved into an intermediate product of 43kDa. One representative of at
least three different experiments is shown. Actin (40kDa) is shown as
loading control. (B) Relative protein expression (%) of FLIP in controls
(black bars) and cycloheximide-treated (white bars) cells. FLIP protein
expression is corrected for actin expression. Protein expression of cells
incubated with cycloheximide is presented in relation to FLIP expression in
the control cells.
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TRAIL sensitivity
To analyse whether chemotherapeutic drugs can modulate TRAIL-
receptor membrane expression, the three cell lines were treated
with cisplatin or interferon-g. Cells were incubated for 24h with 5
and 25mM 5-FU, 5 and 25mM cisplatin and 10 or 100Uml
 1
interferon-g, and the TRAIL-receptor membrane expression was
determined by flow cytometry. Treatment with 5-FU or interferon-
g did not result in a clear upregulation of the TRAIL-receptor
membrane expression in any of the cell lines (Figure 10).
Interferon-g even decreased membrane receptor expression of
Caco-2. Treatment with cisplatin showed a small increase of DR4
and DR5 membrane expression in Caco-2 and Colo320 (Figure 10).
The effect of these modulators on rhTRAIL sensitivity was
studied with the cytotoxicity assay. Treatment of 5-FU, interferon-
g or cisplatin did not show a clear synergistic effect with rhTRAIL
sensitivity in any of these cell lines (Figure 13B and Table 1).
Comparing TRAIL-receptor modulation with CD95-
receptor modulation
The TRAIL-mediated and the CD95-mediated cellular apoptotic
pathways share some characteristics. To analyse whether these
pathways differ in upregulating their membrane receptors, we
studied the effect of 5-FU, cisplatin and interferon-g on the CD95
membrane expression of the cell lines. Basic CD95 membrane
expression levels are demonstrated in Figure 5. CD95 membrane
expression in Colo320 was slightly lower than in SW948. Caco-2
expressed no CD95 receptor on the membrane. Treatment with 5-
FU slightly decreased CD95 membrane expression in Colo320 and
SW948 (Figure 11). Cisplatin increased CD95 surface levels only in
Colo320 (B2 ) (Figure 11), while interferon-g raised CD95
membrane expression in Colo320 and SW948 (6  and 8 ,
respectively) (Figure 12).
Cytotoxicity experiments showed that none of the cell lines were
sensitive to anti-CD95 (Figure 1B). Although both cisplatin and
interferon-g could modulate CD95 membrane expression in
Colo320 and SW948, only SW948 could be sensitised after
treatment with interferon-g (Figures 7and 13). In the presence of
cycloheximide and interferon-g, Colo320 and SW948 became
sensitised to anti-CD95 but not Caco-2. Whereas all SW948 cells
were apoptotic following treatment with cycloheximide, interfer-
on-g (10Uml
 1), and anti-CD95, only B10% of Colo320 cells were
apoptotic following this treatment, a percentage that raised to
B40% of Colo320 cells at the highest interferon-g concentration
used in this study (100Uml
 1) (Figure 7). These findings were
confirmed with Western blot analysis of PARP cleavage (Figure 14).
Western blot analysis showed that treatment with anti-CD95 alone
resulted in a small induction of FLIP-cleaved intermediate product
in SW948, but none in Colo320 or Caco-2 (Figure 9). Cyclohex-
imide in combination with anti-CD95 did not result in a complete
loss of the full-length FLIP-L in SW948, which may be related to
the relatively low percentage of apoptosis as compared to
rhTRAIL-induced apoptosis. As expected, no effect of cyclohex-
imide and anti-CD95 on c-FLIP or PARP cleavage was observed in
Caco-2. These results suggest that CD95 membrane expression
levels are important as is reflected in the higher sensitivity to anti-
CD95 of SW948, the cell line with the highest CD95 membrane
levels following treatment with interferon-g. Intracellular inhibi-
tors are also affecting sensitivity to anti-CD95 but a minimal
expression level of CD95 is required, since the addition of
cycloheximide alone to inhibit the synthesis of short-living
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Figure 10 TRAIL-receptor membrane expression in (A) Caco-2, (B)
Colo320 and (C) SW948 in control cells, after 24h exposure to 5 or 25mM
5-FU, 5 or 25mM cisplatin (CDDP) or 100Uml
 1 interferon-g (IFN).
Membrane expression is determined by flow cytometry and expressed as
MFI. Exposure to 5-FU, cisplatin or interferon-g did not change the
percentage of receptor positive cells. Values are mean7s.d. of at least
three independent experiments.
Table 1 Overview of IC50 values for Caco-2, Colo-320 and SW948 for
rhTRAIL, anti-CD95, cisplatin (CDDP), 5-FU and combinations of these
chemotherapeutic drugs with anti-CD95 or rhTRAIL
IC50
Conditions Caco-2 Colo-320 SW948
TRAIL (mgml
 1) 41.0 41.0 0.00770.001
anti-CD95 (mgml
 1) 41.0 41.0 41.0
CDDP (mM) 8.970.76 2.370.45 4.370.92
anti-CD95+CDDP (mM) 6.471.2 3.871.8 3.670.42
TRAIL+CDDP (mM) 11.373.2 2.570.26 4.470.20
5-FU (mM) 3.070.74 10.676.67 3.070.46
anti-CD95+5-FU (mM) 13.075.0 20.072.2 4.071.95
TRAIL+5-FU (mM) 2.370.6 7.572.1 2.7570.25
1000Uml
 1IFN+TRAIL (mgml
 1) 41.0 41.0 0.00670.001
1000Uml
 1+anti-CD95 (mgml
 1) 41.0 41.0 0.02470.008
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cycloheximide as well as upregulation of CD95 membrane
expression by interferon-g were needed to sensitise Colo320 to
anti-CD95.
DISCUSSION
Different rhTRAIL sensitivities were observed in the three colon
cancer cell lines used in this study. One explanation for this
difference in sensitivity is the different membrane expression of
the TRAIL receptors. The highly TRAIL-sensitive cell line SW948
expresses more DR5 than DR4 on the membrane, whereas the two
relatively resistant lines Caco-2 and Colo320 express DR4 and DR5
at similar levels. Although DcR1 and DcR2 mRNA were detected in
these lines, DcR1 and DcR2 are hardly expressed on the cell
membrane in any of the lines. Therefore, in these cell lines the
ratio of DR4 and DR5 membrane expression might be a more
important factor in determining TRAIL sensitivity than the
expression of decoy receptors on the membrane. Another
explanation for rhTRAIL resistance is a failure of apoptosis
signalling due to mutations or deletions in DR4 or DR5. All known
TRAIL receptors are localised on human chromosome 8p21-22
(Ashkenazi and Dixit, 1998), which is a hot spot for chromosomal
translocations (Mitelman et al, 1997). Deletion or mutational
inactivation of DR4 and DR5 has been reported in cell lines (Kim
et al, 2000; Ozoren et al, 2000) and several human tumour types
(Pai et al, 1998; Shin et al, 2001). However, in both our intrinsic
rhTRAIL-resistant cell lines, apoptosis was observed when the
protein synthesis inhibitor cycloheximide was used. This indicates
that both lines are still able to bind TRAIL and to mediate a death
signal. It is therefore likely that the TRAIL resistance in these lines
is due to an intracellular factor inhibiting the death signal.
Our TRAIL-sensitive cell line SW948 is not sensitive for anti-
CD95 antibody. This illustrates that CD95 and TRAIL pathways
differ, although it is not completely clear at which points. Since
many proteins are involved in both pathways, it has been
suggested that CD95L and TRAIL engage similar, or at least partly
similar, intracellular apoptotic pathways (Velthuis et al, 2002). In
case of apoptosis, we observed caspase 3 activation and PARP
cleavage. However, in the TRAIL- and CD95-resistant cell lines,
caspase 3 activation and thus PARP cleavage was prevented by an
intracellular inhibiting protein. There are several inhibitors known
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Figure 11 CD95-receptor membrane expression in (A) Caco-2, (B)
Colo320 and (C) SW948 in control cells, after 24h exposure to 5 or 25mM
5-fluorouracil (5-FU), 5 or 25mM cisplatin (CDDP) or 100Uml
 1
interferon-g (IFN). Membrane expression is determined by flow cytometry
and is expressed as MFI. Exposure to 5-FU, cisplatin or interferon-g did not
change the percentage at receptor positive cells. Values are mean7s.d. of
at least three independent experiments.
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Figure 12 CD95 membrane expression in Caco-2, Colo320 and
SW948 after exposure to interferon-g.( A) A representative example of
increased CD95 membrane expression in SW948 after exposure to
interferon-g. Increased CD95 expression was detected as an increased
fluorescence intensity of the whole cell population and resulted in a peak
shift to the right. (1¼negative control; 2¼0U m l
 1 interferon-g;
3¼10Uml
 1 interferon-g; 4¼100Uml
 1 interferon-g)( B) CD95
membrane expression in Caco-2 (white bars), Colo320 (grey bars) and
SW948 (black bars) after 24h incubation with interferon-g. CD95
membrane expression is determined by flow cytometry and is expressed
as MFI. Exposure to interferon-g did not change the percentage of receptor
positive cells. Values are mean7s.d. of at least three independent
experiments.
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sto act on the CD95 and the TRAIL pathway. One inhibitor of the
TRAIL signalling pathway is FLIP, which structurally resembles
caspase 8 and can act as an inhibitor of apoptosis when highly
expressed in certain cancers. Human melanoma and colon cancer
cells, resistant to TRAIL, were noted to have increased FLIP
protein levels. A reduction of FLIP levels was associated with an
increased sensitivity to TRAIL-mediated cell death (Zhang et al,
2000; Hernandez et al, 2001). However in another study, no
correlation between FLIP levels and TRAIL sensitivity was
observed for colon cancer cell lines (Lacour et al, 2001). FLIP
antisense oligonucleotides and cycloheximide decreased FLIP
protein and restored TRAIL sensitivity in human multiple
myeloma cells and thyroid cancer cell lines (Mitsiades et al,
2002; Poulaki et al, 2002). All our cell lines became (more)
sensitive to TRAIL in the presence of cycloheximide. This was
associated with a decrease in FLIP protein levels (Figure 9). This
suggests that FLIP is involved in TRAIL resistance, but that the
level of resistance differs per cell line. Xiao et al reported that in
TRAIL-resistant, but not in TRAIL-sensitive glioma cell lines FLIP
was cleaved to produce the p43 fragment after TRAIL exposure
(Xiao et al, 2002). Interestingly, in our study, the p43 fragment was
present in all cell lines following TRAIL exposure, independent of
TRAIL sensitivity. TRAIL resistance may also be determined by
different ratios of c-FLIP to caspase 8 (Harper et al, 2001), but only
in Colo320 the ratio FLIP to caspase 8 was high compared to
SW948. In contrast to FLIP protein levels, cycloheximide did not
affect Bcl-2, Bcl-XL or Bax levels in the cell lines (data not shown),
suggesting that these proteins are not as important as FLIP for
TRAIL resistance in these cell lines.
It is likely that TRAIL resistance arises from the combination of
several factors and not only from the presence of one specific
inhibiting protein. We studied whether the protein expression
levels of several important proteins involved in apoptosis could
explain the difference in TRAIL sensitivity. Key proteins such as
DR4, DR5, FADD, caspase 8 and caspase 3 were expressed in all
cell lines and the apoptosis inhibitor FLIP was expressed similar in
all cell lines. The proteins studied could not clearly reveal a
difference in TRAIL sensitivity.
Treatment with cytotoxic drugs can result in an upregulation of
CD95 receptor and TRAIL receptors on the tumor cell membrane.
The upregulation of CD95 can sensitise tumour cells to the CD95
death signal (Timmer et al, 2002). In the present study, we have
found that cisplatin treatment increased the CD95 membrane
expression. We have investigated whether this can also be an
important mechanism in sensitisation of tumour cells to rhTRAIL.
The colon carcinoma cell lines were exposed to 5-FU or cisplatin.
Chemotherapy is known to be able to augment TRAIL sensitivity
and can result in an upregulation of TRAIL receptors at the mRNA
and protein levels (Sheikh et al, 1998; Keane et al, 1999;
Chinnaiyan et al, 2000; Wu et al, 2000; Nimmanapalli et al,
2001). Besides the reported upregulation of DR4 membrane
expression in erythroleukaemic cells by ionising radiation, little
is known about chemotherapy effects on TRAIL-receptor mem-
brane expression. In the colon cancer cell lines 24h exposure to 5-
FU or cisplatin did not affect TRAIL-receptor membrane expres-
sion or TRAIL sensitivity. In contrast to us others did observe that
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Figure 13 (A) Survival of SW948 to anti-CD95 following continuous
incubation without (closed diamond) and with 1Uml
 1 (closed square),
10Uml
 1 (closed triangle) and 1000Uml
 1 (asterisk) interferon-g
measured by cytotoxicity assays. Values are mean7s.d. of at least three
independent experiments. *: survival of SW948 treated with 10 or
1000Uml
 1 interferon-g differ from the untreated cells after exposure to
anti-CD95 at the concentration of 0.05–1mgml
 1 (Po0.05). (B) Survival
of SW948 to rhTRAIL after continuous incubation without (closed
diamonds), and with 10Uml
 1 (closed square) and 1000Uml
 1 (closed
triangle) interferon-g measured by cytotoxicity assays. Values are
mean7s.d. of at least three independent experiments.
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Figure 14 Western blot analysis of PARP-cleavage in Caco-2, Colo320
and SW948 after exposure to cycloheximide (CHX), anti-CD95 or
cycloheximide in combination with anti-CD95. Cells were 24h preincu-
bated with 100Uml
 1 interferon-g before cycloheximide and anti-CD95
were added. The full-length PARP (112kDa) is cleaved in an 85kDa
fragment.
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2002). This difference might be caused by cell line-specific
characteristics. Lacour et al (2001) also showed that doxorubicin
and cisplatin did not increase membrane DR4 and DR5 expression
in colon cancer cell lines, but did sensitise colon cancer cells to
TRAIL-mediated apoptosis. This also supports the idea that apart
from upregulation of membrane receptor, intracellular factors may
be important to become sensitive to TRAIL-mediated apoptosis.
Interferon-g is known to upregulate CD95 membrane expression
and renders cells susceptible to CD95-mediated apoptosis (Fell-
enberg et al, 1997; Ossina et al, 1997; Koshiji et al, 1998; Ruiz-Ruiz
et al, 2000). Interferon-g raised the CD95 membrane expression
levels only in our two colon cancer cell lines that already expressed
CD95 at the cell surface. The TRAIL-sensitive cell line became
sensitive to anti-CD95 following interferon-g treatment. However,
intracellular effects of interferon-g on the sensitivity to anti-CD95
by either an upregulation of caspases or downregulation of Bcl-2
and Bcl-XL cannot be excluded (Fellenberg et al, 1997; Ossina et al,
1997; Ruiz-Ruiz et al, 2000; Varela et al, 2001). Interferon-g did not
affect TRAIL-receptor membrane expression or TRAIL sensitivity
in our cell lines.
The safety of soluble rhTRAIL without a His-tag or a Flag-tag in
chimpanzees, its antitumour efficacy alone and its potentiation
effect with chemotherapy (Walczak et al, 1999) makes rhTRAIL an
interesting anticancer agent. The present study demonstrates that
chemotherapy (or interferon-g) affects the TRAIL and CD95
pathway differently. Upregulation of DR4 and DR5 on the surface
has not been detected, but removal of intracellular blocks can
increase TRAIL sensitivity. On the other hand, upregulation of
CD95 receptor on the surface has been observed and can increase
anti-CD95 sensitivity. In conclusion, our results demonstrate that
anticancer agents modulate the CD95 and TRAIL receptors in
different ways. Overcoming intracellular inhibiting factors, such as
FLIP, is another option to sensitise tumour cells to TRAIL-
mediated apoptosis, especially in cells impaired in drug-induced
upregulation of TRAIL receptors on the cell surface.
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